The Oxford Universiy will start an interim analysis of data from its late-stage trial of the experimental vaccine after 53 infections among its volunteers, the study's chief investigator said on Thursday. The Oxford Vaccine Group's director, Andrew Pollard, said there were "lots of cases" of infections in its Phase III trial in Britain, Brazil and South Africa. Pollard's comments came after data published on Thursday showed the Oxford/AstraZeneca vaccine in Phase II studies produced a strong immune response in older adults. Earlier on Thursday, he said he expected Phase III data to be released by Christmas. Data released in July showed the vaccine generated robust immune responses in adults aged 18 to 55.

Source: Mint November 19, 2020 11:19 UTC